Abstract
Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems—such as speech and language, social–emotional development, and learning difficulties—for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.
| Original language | English |
|---|---|
| Journal | The Lancet Oncology |
| Volume | 20 |
| Issue number | 1 |
| Pages (from-to) | 29-41 |
| Number of pages | 13 |
| ISSN | 1470-2045 |
| DOIs | |
| Publication status | Published - 01.2019 |
Funding
We thank the following experts of the International Late Effects of Childhood Cancer Guideline Harmonization Group and other members for their participation in the international guideline harmonization process: Nina Kadan-Lottick, Gill Levitt, Alex Hoetink, John Mussman, and Aimilia Tsirou for critically appraising the recommendations and manuscript. We would like to thank the PanCareLIFE consortium. We also thank the National Cancer Institute for supporting the work of the Children's Oncology Group ( National Clinical Trials Network Group Operations Center Grant U10CA180886 ). ECvD reports grants from Stichting Kinderen Kankervrij during the study. PRB reports personal fees from Fennec Pharmaceuticals outside the submitted work. EC, AaZD, RS, MMvdHE, RLM, and LCK received support from the 7th Framework Programme of the EU (PanCareLIFE). MMH is supported by a Cancer Center Support grant (CA21765) to St Jude Children's Research Hospital and the American Lebanese Syrian Associated Charities. RLM received funding from the Dutch Cancer Society. AW received support from the Swiss Cancer League. KK is supported by a Veteran Affairs Merit Review Grant and US National Institutes of Health. The remaining authors have nothing to declare.
Research Areas and Centers
- Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)
